Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Nov 2;73(9):1634-1641.
doi: 10.1093/cid/ciab426.

If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study

Mark Beldman  1 , Claudia Löwik  1 , Alex Soriano  2 , Laila Albiach  2 , Wierd P Zijlstra  3 , Bas A S Knobben  4 , Paul Jutte  1 , Ricardo Sousa  5 , André Carvalho  5 , Karan Goswami  6 , Javad Parvizi  6 , Katherine A Belden  7 , Marjan Wouthuyzen-Bakker  8
Affiliations
Observational Study

If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study

Mark Beldman et al. Clin Infect Dis. .

Erratum in

Abstract

Background: Rifampin is generally advised in the treatment of acute staphylococcal periprosthetic joint infections (PJI). However, if, when, and how to use rifampin remains a matter of debate. We evaluated the outcome of patients treated with and without rifampin, and analyzed the influence of timing, dose and co-antibiotic.

Methods: Acute staphylococcal PJIs treated with surgical debridement between 1999 and 2017, and a minimal follow-up of 1 year were evaluated. Treatment failure was defined as the need for any further surgical procedure related to infection, PJI-related death or the need for suppressive antimicrobial treatment.

Results: A total of 669 patients were analyzed. Treatment failure was 32.2% (131/407) in patients treated with rifampin and 54.2% (142/262) in whom rifampin was withheld (P < .001). The most prominent effect of rifampin was observed in knees (treatment failure 28.6% versus 63.9%, respectively, P < .001). The use of rifampin was an independent predictor of treatment success in the multi-variate analysis (OR 0.30, 95% CI 0.20 - 0.45). In the rifampin group, the use of a co-antibiotic other than a fluoroquinolone or clindamycin (OR 10.1, 95% CI 5.65 - 18.2) and the start of rifampin within 5 days after surgical debridement (OR 1.96, 95% CI 1.08 - 3.65) were predictors of treatment failure. The dosing of rifampin had no effect on outcome.

Conclusions: Our data supports the use of rifampin in acute staphylococcal PJIs treated with surgical debridement, particularly in knees. Immediate start of rifampin after surgical debridement should probably be discouraged, but requires further investigation.

Keywords: acute; failure; periprosthetic joint infection; rifampin; staphylococci.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival curve rifampin versus no-rifampin. Survival curve rifampin (n = 407) versus no-rifampin (n = 262) depicted according to treatment failure (A) and clinical failure (B) as defined in the material and method section.
Figure 2.
Figure 2.
Treatment failure (A) and clinical failure (B) rifampin versus no-rifampin according to the type of joint.
Figure 3.
Figure 3.
Timing of rifampin after surgical debridement.
Figure 4.
Figure 4.
Treatment failure according to the co-antibiotic administered with rifampin.
See this image and copyright information in PMC

Comment in

References

    1. Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on Periprosthetic Joint Infection. Bone Joint J 2013; 95-B:1450–2. - PubMed
    1. Osmon DR, Berbari EF, Berendt AR, et al. ; Infectious Diseases Society of America . Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1–e25. - PubMed
    1. Lora-Tamayo J, Murillo O, Iribarren JA, et al. ; REIPI Group for the Study of Prosthetic Infection . A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013; 56:182–94. - PubMed
    1. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162:96–102. - PubMed
    1. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537–41. - PubMed

Publication types